Behcet's disease and its oral manifestations

Dentistry Today

Volumn 23, Issue 6, 2004, Pages 92-95

  Georgaklis, Clifton C ^a  

^a Adult Cosmetic Orthodontics ^*

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; AZATHIOPRINE; CHLORAMBUCIL; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOTOXIC AGENT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; PENTOXIFYLLINE; STEROID; THALIDOMIDE; TSUKUBAENOLIDE;

AUTOIMMUNE DISEASE; BEHCET DISEASE; CLINICAL FEATURE; EYE INJURY; GENETIC ANALYSIS; HUMAN; MOUTH LESION; REVIEW; SKIN DEFECT; UNITED STATES;

ADULT; ANTI-INFLAMMATORY AGENTS; BEHCET SYNDROME; COLCHICINE; FEMALE; HUMANS; ORAL ULCER; PREDNISONE;

EID: 3142705642     PISSN: 87502186     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (18)

1. Mishima S, Masuda K, Izawa Y, et al. The eighth Frederick H. Verhoeff Lecture. Presented by Saiichi Mishima, MD. Behcet's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc. 1979;77:225-279.
2. Yazici H. Behcet's syndrome. In: Klippel JH, Dieppe PA, eds. Rheumatology. London, England: Mosby; 1994:6.20.1-6.20.6.
3. Burton-Kee JE, Mowbray JF, Lehner T. Different cross-reacting circulating immune complexes in Behcet's syndrome and recurrent oral ulcers. J Lab Clin Med. 1981;97:559-567.
4. Lee S, Bang D, Lee E-S, Sohn S, eds. Behcet's Disease: A Guide to Its Clinical Understanding, Berlin, Germany: Springer Verlag; 2001:17.
5. Ono S, Aoki K, Sugiura S, et al. Letter: HL-A5 and Behcet's disease. Lancet. 1973;2:1383-1384.
6. Yazici H, Chamberlain MA, Schreuder I, et al. HLA antigens in Behcet's disease: a reappraisal by a comparative study of Turkish and British patients. Ann Rheum Dis. 1980;39:344-348.
7. Chajek T, Fainaru M. Behcet's disease. Report of 41 cases and a review of the literature. Medicine (Baltimore). 1975;54:179-196.
8. Alpsoy E, Yilmaz E, Basaran E. Interferon therapy for Behcet's disease. J Am Acad Dermatol. 1994;31:617-619.
9. Kötier I, Eckstein AK, Stübiger N, et al. Treatment of ocular symptoms of Behcet's disease with interferon a2a: a pilot study. Br J Ophthalmol. 1998;82:488-494.
10. Yasui K, Ohta K, Kobayashi M, et al. Successful treatment of Behcet disease with pentoxifylline. Ann Intern Med. 1996;124:891-893.
11. Gardner-Medwin JM, Smith NJ, Powell RJ. Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behcet's disease: use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis. 1994;53:828-832.
12. International Study Group for Behcet's Disease. Criteria for diagnosis of Behcet's disease. Lancet. 1990;335:1078-1080.
13. Mamo JG. The rate of visual loss in Behcet's disease. Arch Ophthalmol. 1970;84:451-452.
14. Ersoy F, Berkel A, Firat T, et al. HLA antigens associated with Behcet's Disease. In: Dausset J, Svejgaard A, eds. HLA and Disease. Baltimore, Md: Williams & Wilkins; 1977.
15. Koc Y, Gullu I, Akpek G, et al. Vascular involvement in Behcet's disease. J Rheumatol. 1992;19:402-410.
16. Yazici H, Chamberlain MA, Schreuder I, et al. HLA antigens in Behcet's disease: a reappraisal by a comparative study of Turkish and British patients. Ann Rheum Dis. 1980;39:344-348.
17. Hooper PL, Rao NA, Smith RE. Cataract extraction in uveitis patients. Surv Ophthalmol. 1990;35:120-144.
18. Ammann AJ, Johnson A, Fyfe GA, et al. Behcet syndrome. J Pediatr. 1985;107:41-43.